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Commentingtoolbarshouldbedisplayedautomatically; if
not,clickon‘Tools’,select‘Comment&Markup’,thenclick
on ‘Show Comment & Markup tool bar’ (or ‘Show
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Commenting tool bar. Click to set the cursor
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Commenting toolbar.Tohighlight the text tobe
replaced, clickanddrag the cursorover the text.
Then simply type in the replacement text. The
replacementtextwillappearinacommentingbox.
YoumayalsocutͲandͲpastetextfromanotherfile
into this box. To replace formatted text (an
equation for example) please Attach a file (see
below).
Click the ‘Replace (Ins)’ icon  on the
Comment tool bar. To highlight the text to be
replaced, clickanddrag the cursorover the text.
Then simply type in the replacement text. The
replacementtextwillappearinacommentingbox.
YoumayalsocutͲandͲpastetextfromanotherfile
into this box. To replace formatted text (an





to be deleted. Then press the delete button on
yourkeyboard.Thetexttobedeletedwillthenbe
struckthrough.
Click the ‘Strikethrough (Del)’ icon  on the
Commenttoolbar.Clickanddragoverthetextto
bedeleted.Thenpressthedeletebuttononyour





Click on the ‘Highlight’ button  on the
Commentingtoolbar.Clickanddragoverthetext.
To make a comment, double click on the
highlightedtextandsimplystarttyping.







formatted text to be replaced. A window will
automaticallyopenallowingyoutoattachthefile.
To make a comment, go to ‘General’ in the
‘Properties’ window, and then ‘Description’. A
graphicwill appear in the PDF file indicating the
insertionofafile.
Click on the ‘Attach File’ icon  on the
Comment tool bar. Click on the figure, table or
formatted text to be replaced. A window will
automaticallyopenallowingyoutoattachthefile.
Agraphicwillappear indicating the insertionofa
file.
Leaveanote/
comment Clickonthe ‘NoteTool’button on
theCommentingtoolbar.Clicktosetthelocation
of the note on the document and simply start
typing.Donotusethisfeaturetomaketextedits.







Review To review your changes, click on the ‘Show’
button  on the Commenting tool
bar.Choose ‘ShowCommentsList’.Navigateby
clickingonacorrection inthe list.Alternatively,
double click on any markͲup to open the
commentingbox.
Yourchangeswillappearautomatically ina list
below the Comment tool bar. Navigate by
clickingonacorrection inthe list.Alternatively,





Toundoany changesmade,use the right click
buttononyourmouse(forPCs,CtrlͲClickforthe
Mac). Alternatively click on ‘Edit’ in themain
Adobe menu and then ‘Undo’. You can also
deleteeditsusingtherightclick(CtrlͲclickonthe
Mac)andselecting‘Delete’.
Toundoany changesmade,use the right click
buttononyourmouse(forPCs,CtrlͲClickforthe
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80
81There is evidence that it is safe and effective for patients with inﬂammatory bowel diseases
(IBD) to switch from maintenance therapy with an original inﬂiximab drug to a biosimilar, but
little is known about outcomes of reverse switches and/or multiple switches. We aimed to








90We performed a prospective observational study of 174 unselected and consecutive patients
with IBD (136 with Crohn’s disease [CD] and 38 with ulcerative colitis [UC]) who received
maintenance therapy with the biosimilar in Hungary. In September 2017, patients were
switched from the biosimilar (CT-P13) to Remicade, due to reimbursement policies. In our
cohort, 8% (n [ 14) patients had been previously exposed to the originator Remicade. We
collected clinical and biochemical information from patients at baseline (time of the switch)
and 16 and 24 weeks thereafter. Clinical remission was deﬁned as a Crohn’s disease activity
index <150 points or no ﬁstula drainage, or a partial Mayo score <3 points for patients with UC.










101There was no signiﬁcant difference in the proportion of patients in clinical remission at week 8
before the switch (82.5% with CD and 82.9% with UC), at baseline (80.6% with CD and 81.6%
with UC), at week 16 (77.5% with CD and 83.7% with UC), or at week 24 (CD 76.3% with CD and
84.9% with UC) (P [ .60 among groups for patients with CD and P [ .98 among groups for
patients with UC). For all patients, mean serum trough levels of inﬂiximab were 5.33 – 4.70 mg/
mL at baseline and 5.69 – 4.94 mg/mL at week 16 (P [ .71); we did not ﬁnd signiﬁcant dif-
ferences in prevalence of anti-drug antibody at baseline (16.2%) compared with week 16
(16.9%) (P[ .87). Four infusion reactions occurred, until week 24 of follow up. There was no
difference in outcomes or trough or antidrug antibody levels between patients with or without
previous exposure to Remicade.102
103CONCLUSIONS:104
105We collected data from a real-life cohort of patients with CD or UC who were switched from
maintenance therapy with a biosimilar to Remicade or were treated with only Remicade. No
signiﬁcant changes were observed in remission, trough levels, or antidrug antibodies in pa-
tients switched from the biosimilar to Remicade. No new safety signals were detected.106107
108Keywords: Outcome; Originator Drug; TNF Antagonist; Drug Monitoring.109hip.
er: ADA, anti-drug antibody; CD, Crohn’s
e Activity Index; IBD, inﬂammatory bowel
terquartile range; NEAK, National Health
ayo, partial Mayo; TDM, therapeutic drug
monitoring; TL, trough level; TNF, tumor necrosis factor; UC, ulcerative
colitis.
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What You Need to Know
Background
There is evidence that it is safe and effective for
patients with inﬂammatory bowel disease to switch
from maintenance therapy with an original inﬂiximab
drug to a biosimilar drug, but little is known about
outcomes of reverse switches or multiple switches.
We studied the effects of a reverse switch (from a
biosimilar to Remicade) in a real-life cohort.
Findings
We found no signiﬁcant changes in remission, trough
levels, or anti-drug antibodies in patients switched
from the biosimilar to Remicade. Good medium-term
drug sustainability was observed, with no new safety
signals.
Implications for patient care
In a real-life cohort of patients with inﬂammatory
bowel disease, we found no signiﬁcant changes in
patients switched from a biosimilar to Remicade. As
the number of biosimilar agents on the market in-
creases, data on reverse or multiple switches are
needed to guide decision making and provide infor-
mation on their interchangeability.




















































































































232Biological agents represent a fundamental step inthe therapy of inﬂammatory bowel disease (IBD).
Inﬂiximab (brand name Remicade) is a monoclonal
antibody directed against tumor necrosis factor (TNF)
alpha that has shown distinct efﬁcacy in patients with
Crohn’s disease (CD) and ulcerative colitis (UC).1,2 The
global expenditure on biological treatments approaching
almost unaffordable costs,3 and the recent expiry of
patents for biologics has led to the development of bio-
similar products. CT-P13 was the ﬁrst inﬂiximab (IFX)
biosimilar to be approved with the same therapeutic in-
dications as its originator product by the European Med-
icines Agency and later by the U.S. Food and Drug
Administration.4,5
The acceptance of biosimilars among physicians
encountered some resistance in the past few years,
especially when considering switching from the origi-
nator product to its biosimilar. To date, data accumulated
from real-life cohorts and randomized controlled trials
on the clinical efﬁcacy, safety, and immunogenicity of
biosimilar CT-P13 show comparable outcomes with the
originator IFX in both anti-TNF-naïve and switched
patients.6–15 In January 2017, the ECCO presented a
position statement on biosimilars and concluded that
there are no clinically meaningful differences between
CT-P13 and the originator IFX regarding efﬁcacy and
safety and switching from the originator to an approved
biosimilar product is acceptable.16 Nonetheless, physi-
cians may need to also consider reverse switching
(switch back to the originator product) or cross-
switching, multiple switching among biosimilars in the
near future. This tendency will potentially result in a
continuous change in prescription preferences of anti-
TNF drugs, highlighting the importance of pharmacovi-
gilance. Evidence is currently lacking regarding reverse
switching, multiple switching, and cross-switching
among biosimilars in IBD patients.
The biosimilar IFX CT-P13 (brand name Inﬂectra)
entered the Hungarian market in 2014 and was adopted
for reimbursement by the National Health Insurance
Fund of Hungary (NEAK).17 The use of biosimilar IFX
was mandatory in Hungary between May 2014 and
September 2017 in all anti-TNF-naïve patients and in
patients who were previously treated with the originator
product with proven clinical beneﬁt but have been on
drug holiday for longer than 12 months. Last year, the
national tender for IFX therapy reimbursement by the
NEAK has been won by Remicade, and as a consequence
the originator became the only fully reimbursed IFX
biologic agent in Hungary after September 2017.18 Due
to this policy change, a nationwide nonmedical reverse
switch was carried out in all IBD patients from the bio-
similar to the originator IFX.
The aim of the present study is to evaluate short-term
drug sustainability, efﬁcacy, safety, and immunogenicity
proﬁle of reverse switching from a biosimilar to the
originator IFX in consecutive IBD patients in a multi-
center real-life IBD cohort.FLA 5.5.0 DTD  YJCGH56271_proof Materials and Methods
This is a multicenter prospective observational study
enrolling unselected and consecutive patients who were
switched from the biosimilar IFX CT-P13 (Inﬂectra) to
the originator Remicade during maintenance therapy.
Patients received intravenous infusions of IFX (5 mg/kg
or 10 mg/kg of body weight) every 8 weeks. The inclu-
sion started in September 2017, when Remicade became
the only available IFX biologic agent in Hungary, and thus
the mandatory reverse switch to the originator was
initiated. Four referral IBD centers participated in the
study: 3 university centers and 1 county hospital.
Patient demographics, previous and concomitant
medications were recorded, disease location and
behavior in CD and disease extent in UC were assessed
according to the Montreal classiﬁcation.19 A harmonized
monitoring strategy was applied in all participating
centers, as requested by the NEAK. Clinical and
biochemical assessment was performed at baseline or
switch and 16 and 24 weeks thereafter. Clinical remis-
sion was deﬁned as a Crohn’s Disease Activity Index
(CDAI) <150 points or no ﬁstula drainage as assessed by
the ﬁstula drainage assessment in CD and as a partial
Mayo (pMayo) score of <3 points in UC.2,20,21 Patients
with induction treatment at baseline were excluded from
the clinical activity assessment. Biochemical activity was
evaluated using serum C-reactive protein (normal cutoff
10 mg/L). Infusion-related adverse events were regis-
tered at baseline and weeks 8, 16, and 24.16 April 2019  6:21 pm  ce OB
Table 1. Baseline Patient Characteristics
CD (n ¼ 136) UC (n ¼ 38)
Female/male 67/69 (49.3/50.7) 16/21 (44.7/55.3)
Age at disease onset, y 27.5 (20–32.7) 25 (19.5–34.25)
Disease duration, y 8 (4-14) 7 (4-14)
Location (L1/L2/L3/all L4) 11.0/32.4/56.6/10.7 —
Extent (E1/E2/E3) — 5.4/40.5/54.1





Concomitant steroid/AZA 8.8/50.7 27.0/35.1
Previous anti-TNFa 19.9 16.2
Originator IFX (Remicade) 8.1 7.9
Biosimilar IFX (Inﬂectra) 1.5 —
Adalimumab 7.4 5.3
Both IFX (Remicade) and
adalimumab
2.9 —
Values are n (%),median (interquartile range), or %.
AZA, azathioprine; CD, Crohn’s disease; IFX, inﬂiximab; TNF, tumor necrosis
factor; UC, ulcerative colitis.
aAll patients who were previously exposed to the originator IFX had been on a
drug holiday for at least 12 months before the initiation of their current IFX
treatment regimen.





















































































































Serum drug trough level (TL) and anti-drug antibody
(ADA) were measured at baseline and week 16. Patients
with induction treatment at baseline or dose intensiﬁ-
cation or de-escalation during follow-up were excluded
from the analysis of therapeutic drug monitoring (TDM).
For the measurement of IFX TL and ADAs, conventional
and bridging enzyme-linked immunosorbent assay
methods were used (Lisa-Tracker inﬂiximab LT-005
Duo; Theradiag, Croissy-Beaubourg, France). The detec-
tion cutoff value of IFX TL was 0.1 mg/mL. Therapeutic
IFX TL was deﬁned between 3 and 7 mg/mL. The cutoff
value of ADA detection was 10 ng/mL as deﬁned by the
enzyme-linked immunosorbent assay kit. For better
stratiﬁcation of patients, we deﬁned the ADA titer >200
ng/mL as “high” ADA titer. The enzyme-linked immu-
nosorbent assay measurements were centralized and
performed at the Department of Laboratory Medicine,
Semmelweis University.
Statistical Analysis
Data were analyzed with the use of SPSS 20.0 soft-
ware (IBM Corporation, Armonk, NY). Descriptive sta-
tistics were used to characterize patients’ demographics,
clinical remission and disease activity rates, and adverse
events. Clinical remission rates and ADA positivity rates
were compared by chi-square test or Fisher exact test.
Biochemical response and inﬂiximab TLs were evaluated
by 1-way analysis of variance, using Scheffé post hoc
analysis, t test with separate variance estimates, and
Mann–Whitney U test. The value of P < .05 was
considered statistically signiﬁcant.
Ethical Considerations
Ethical approval was acquired from the National Ethical
Committee 929772-2/2014/EKU (292/2014). Written
informed consent was obtained from all participants.
Results
A total of 174 IBD patients (136 CD and 38 UC) were
included in this cohort. Patient characteristics at baseline
are shown in Table 1. Complicated disease behavior and
perianal manifestation was present in 39.7% and 48.5%
of CD patients. 54.1% of UC patients had extensive colitis.
Concomitant steroid and immunosuppressive therapy
(azathioprine) was present in 8.8% and 50.7% and
27.0% and 35.1% of CD and UC patients at baseline,
respectively. Previous anti-TNF use was 19.9% and
16.2% in CD and UC patients, respectively. A total of 11%
and 7.9% of CD and UC patients, respectively, have
already been exposed to the originator IFX previously.
Previous resective surgery rates were 26.1% among CD
patients.FLA 5.5.0 DTD  YJCGH56271_proof Clinical Outcomes and Drug Sustainability After
Reverse Switch
A total of 129 CD and 38 UC patients had available
clinical data at baseline. Median CDAI and pMayo scores
were 57 (IQR, 32–112) and 1 (IQR, 0–2) at baseline and
switch; 68 (IQR, 35–125.5) and 1 (IQR, 0–1) at week 16;
and 60 (IQR, 31–100) and 1 (IQR, 0–2) at week 24.
Median clinical activity scores and mean C-reactive
protein levels during the complete follow-up period are
shown in Table 2. Mean CDAI and pMayo scores at week
8, baseline, week 16, and week 24 were compared, with
1-way analysis variance analysis showing no statistically
signiﬁcant variance between clinical activity scores (CD:
P ¼ .53; UC: P ¼ .57). Mean C-reactive protein levels also
showed no statistically signiﬁcant difference throughout
the follow up-period (CD: P ¼ .23; UC: P ¼ .53).
The change in clinical disease activity based on CDAI
and pMayo scores during follow-up are presented in
Figures 1 and 2; 90.3% of all patients who were in
clinical remission at switch and baseline sustained
clinical remission up to week 16 and 88.2% up to week
24. There was no signiﬁcant difference between the
proportion of patients in clinical remission at week 8
before switch, at switch and baseline, and at week 16
and 24 (CD: 82.6%, 80.6%, 77.5%, and 76.3%, respec-
tively, P ¼ .60; UC: 82.9%, 81.6%, 83.7%, 84.8%,
respectively, P ¼ .98). Three patients required dose
optimization between baseline and week 16; however
none of them were in clinical remission at baseline. Of
note, concomitant low-dose (10 mg) steroid use in UC
and CD patients with remission at baseline (n ¼ 7 of 31,16 April 2019  6:21 pm  ce OB
Table 2. Clinical and Biochemical Activity During Follow-Up
Patients on Maintenance IFX Therapy Week 8 Before Switcha Switch/Baseline Week 16 Week 24a
CD n ¼ 115 n ¼ 129 n ¼ 118 n ¼ 98
CDAI 52.5 (30.25–99.25) 57 (32–112) 68 (35–125.5) 60 (31–100)
CRP 9.89  13.21 8.74  12.88 8.41  9.79 6.69  6.56
UC n ¼ 34 n ¼ 38 n ¼ 35 n ¼ 30
pMayo 1 (0–2) 1 (0–2) 1 (0–1) 1 (0–2)
CRP 5.06  5.74 4.73  5.17 7.47  10.66 5.99  6.26
Values are mean  SD or median (interquartile range).
CD, Crohn’s disease; CDAI, Crohn’s Disease Activity Index; CRP, C-reactive protein; IFX, inﬂiximab; LOR, loss of response; pMayo, partial Mayo; UC, ulcerative
colitis.
bLost Q9to follow-up (up to week 16): n ¼ 5 patients discontinue IFX due to LOR (active disease at baseline), n ¼ 1 patient discontinue IFX due to LOR (remission at
baseline), n ¼ 3 patients presented infusion reaction, n ¼ 2 patients underwent surgery (active disease at baseline).
cLost to follow-up (after week 16): n ¼ 1 patient discontinue IFX due to LOR (remission at baseline), n ¼ 1 patient discontinue IFX due to LOR (active disease at
baseline), n ¼ 1 patient underwent surgery (active disease at baseline), n ¼ 1 patient presented infusion reaction, n ¼ 1 patient had suspected malignancy, n ¼ 1
patient was lost to follow-up.
dLost to follow-up (up to week 16): n ¼ 2 patients discontinue IFX due to LOR (active disease at baseline), n ¼ 1 patient was lost to follow-up.
eLost to follow-up (after week 16): n ¼ 1 patient discontinue IFX due to LOR (active disease at baseline).








































































































43622.6%; n ¼ 6 of 104, 5.8%, respectively) was not pre-
dictive for clinical relapse at weeks 16 and 24.
Clinical outcomes were not different in the cohort of
patients with a previous exposure to the originator IFX
(13.9% of all patients, n ¼ 18; clinical remission rates at
week 8 before switch, at switch and baseline, and at
week 16 and 24 were 86.7%, 100%, 94.4%, and 93.3%,
respectively; P ¼ .46) or in patients with the biosimilar
IFX as ﬁrst IFX (82.4%, 78.5%, 77.0%, and 76.7%,










447TDM: TLs and Immunogenicity After Reverse
Switch
Serum IFX TLs and ADAs of all IBD patients receiving
week 16 infusion are presented in Table 3. No signiﬁcant
difference was observed in mean serum IFX TLs between
switch and baseline and week 16 (5.33  4.70 mg/mL vs
5.69  4.94 mg/mL; P ¼ .71). Patients were stratiﬁed
based on subtherapeutic serum IFX TLs (<3 mg/mL),Figure 1. Clinical activity before and after reverse switch in
IBD patients in remission at switch *Week 8 data before
baseline and week 24 data are only available from 3 centers.
Two patients were lost to follow-up. LOR, loss of response.
FLA 5.5.0 DTD  YJCGH56271_proof adequate serum IFX TLs (7 mg/mL  TL 3 mg/mL), and
supratherapeutic serum IFX TLs (> 7 mg/mL) as shown
in Supplementary Figure 1. Mean serum IFX TLs were














Figure 2. (A) Clinical activity before and after reverse switch in
CD patients. *Week 8 data before baseline and week 24 data
are only available from 3 centers. One patient was lost to
follow-up. (B) Clinical activity before and after reverse switch
in UC patients. *Week 8 data before baseline and week 24
data are only available from 3 centers. One patient was lost
to follow-up. LOR, loss of response.


















Table 3. Trough Levels and Anti-Drug Antibodies in IBD Patients















Serum IFX trough level, mg/mL 5.33  4.70 5.69  4.94
5.34  4.62 5.26  5.31 5.49  4.62 6.87  6.52
Anti-drug antibody positivity (>10 ng/mL)
16.2 16.9
High anti-drug antibody positivity (>200 ng/mL)c
8.5 8.5
Values are mean  SD or %.
IBD, inﬂammatory bowel disease; IFX, inﬂiximab.
aIFX dose: 5 mg/kg of body weight.
bIFX dose: 10 mg/kg of body weight.
c Q10.
Table 4. Adverse Events in Patients With Reverse Switch and
Drug Sustainability in Patients in Clinical Remission










events (n ¼ 174)
Infusion reaction 1 2 0 1
Anaphylaxis 0 0 0 0
Drug sustainability in patients with remission at switch
(n ¼ 142)
Patients discontinued IFX treatment up to week 16
LOR, clinical relapse 1 (0.7)
Infusion reaction 3 (2.1)
Patients discontinued IFX treatment up to week 24
LOR, clinical relapse 2 (1.4)
Infusion reaction 3 (2.1)
Values are n or n (%).
IFX, inﬂiximab; LOR, loss of response.




















































































































580patients at baseline vs week 16 (P ¼ .59); and 6.66 
5.41 mg/mL vs 6.81  5.84 mg/mL for UC patients (P ¼
.92) (Supplementary Tables 1 and 2)
Stratiﬁcation of CD and UC patients based on sub-
therapeutic, adequate and supratherapeutic TLs are
shown in Supplementary Figures 2 and 3. No signiﬁcant
differences were observed in ADA formation (overall
ADA positivity: 16.2% vs 16.9% at baseline and week
16, P ¼ .87; rates of high ADA positivity: 8.5% and
8.5%, P ¼ 1). One CD patient developed high ADA
positivity (>200 ng/mL) from ADA-negative status at
baseline.
Fourteen patients with TDM at baseline and week 16
of this cohort have previously been exposed to the
originator IFX. All patients had been on a drug holiday
for at least 12 months before the initiation of their cur-
rent IFX treatment regimen. By separately analyzing
these patients, also no statistically signiﬁcant difference
was observed between baseline and week 16 TLs (6.51
 4.65 mg/mL vs 8.11  4.44 mg/mL, P ¼ .25). ADA
positivity rates were also identical at baseline and week
16 (14.3%; n ¼ 2 for both).
The rate of concomitant azathioprine therapy
remained unchanged during the follow-up period. By
separately analyzing patients with combined immu-
nosuppressive therapy and IFX monotherapy, there
were no statistically signiﬁcant differences between
baseline and week 16 TLs in either group. Mean TLs
were somewhat higher among azathioprine-treated
patients at baseline (5.80 mg/mL vs 4.86 mg/mL; P ¼
.13), and signiﬁcantly higher at week 16 (6.63 mg/mL
vs 4.76 mg/mL; P ¼ .006) as well. There were also no
statistically signiﬁcant differences in ADA positivity
rates at baseline compared with week 16 by analyzing
combined and monotherapy separately. However, ADA
positivity was signiﬁcantly lower in patients with
combined immunosuppression at both baseline (4.6%
vs 27.7%; P ¼ .001) and week 16 (7.7% vs 26.2%;
P ¼ .005).FLA 5.5.0 DTD  YJCGH56271_proof Adverse Events After Reverse Switch
A total of 174 patients were evaluated for infusion
related adverse events. Three infusion reactions occurred
up to week 16 follow-up and altogether 4 infusion re-
actions up to week 24 (Table 4). No anaphylactic reaction
was observed. All patients with infusion reaction had
detectable ADAs at baseline and none of these patients
have previously been exposed to the originator IFX. Drug
sustainability in patients with clinical remission at base-
line and switch is presented in Table 4.Discussion
As the registration clinical trials for CT-P13 were
performed in non-IBD patients, signiﬁcant amount of16 April 2019  6:21 pm  ce OB
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696postmarketing data have accumulated in the past few
years on the biosimilar IFX. Results from real-word
observational cohorts and randomized controlled trials
evaluating IFX naïve patients and switching showed that
the biosimilar IFX CT-P13 is effective and safe in
inducing and maintaining clinical remission in CD and
UC. Immunogenicity and pharmacokinetic proﬁle of CT-
P13 is comparable to that of the originator product and
there have been no reports that switching from the
originator to the biosimilar IFX would have any mean-
ingful effect on clinical efﬁcacy or safety.6–14
The most compelling data are reported by Kim et al12
in a phase III randomized controlled trial comparing CT-
P13 with the originator IFX in patients with active CD. A
total of 220 patients were randomized to 4 groups;
maintenance groups (CT-P13 vs originator IFX) and
switching groups (CT-P13 to originator IFX vs originator
IFX to CT-P13; switch was performed at week 30). Rates
of CDAI-70 response, CDAI-100 response and clinical
remission were similar for CT-P13 and the originator IFX
at week 30. At week 54, clinical remission as well as
CDAI-70 response rates were maintained, results were
comparable in all 4 treatment groups. There were no
meaningful differences in ADA positivity rates between
the treatment groups. One-year safety including adverse
drug reactions, serious adverse events, and infections
was similar among all treatment groups.12 The NOR-
SWITCH study evaluated the clinical efﬁcacy and safety
of the biosimilar IFX through 52 weeks after switching
from the originator in a merged cohort of multiple
immune-mediated diseases including IBD; however, the
study was not powered to allow for conclusions on
individual diseases.11 In the 26-week open label NOR-
SWITCH EXTENSION part of the study,13 treatment efﬁ-
cacy, safety, and immunogenicity were assessed
regarding CT-P13 treatment throughout the 78-week
study period (maintenance group) compared with
switching from the originator IFX to CT-P13 at week 52
(switch group). The primary endpoint was overall dis-
ease worsening during follow-up. Exploratory subgroup
analyses of IBD (124 CD and 74 UC patients) showed that
disease worsening occurred in 20.6% and 13.1% in CD
patients and in 15.4% and 2.9% in UC patients in the
maintenance and switch groups, respectively. These re-
sults were within the predeﬁned noninferiority margin of
15%. The incidence of adverse events and ADA rates
were comparable between arms.13 Another recent pro-
spective trial is the SECURE trial22 with the objective to
demonstrate the noninferiority of IFX serum concentra-
tions of biosimilar IFX CT-P13 (Remsima) to IFX con-
centrations of Remicade. No signiﬁcant changes were
observed in IFX TLs (ratio of biosimilar and originator
IFX serum concentrations: 107.6% [90% conﬁdence in-
terval, 97.44–118.81] and 110.1% [90% conﬁdence in-
terval, 95.99–126.29] for CD and UC, respectively).23
The SB2 IFX biosimilar has recently been approved by
the European Medicines Agency and the Food and Drug
Administration for all indications of the originatorFLA 5.5.0 DTD  YJCGH56271_proof product, as well.24,25 Fischer et al23 performed a study on
clinical outcomes and immunogenicity analysis following
a switch from originator IFX (Remicade) to the biosimilar
SB2 (Flixabi). Median change in disease activity was
0 (interquartile range [IQR], –0.8 to 1.8) at week 16 and
1 (IQR, 0.0 to 2.0) at week 24 in CD; 0 (IQR, –1.0 to 0.0)
at week 16 and 0 (IQR, –1.0 to 0.0) at week 24 in UC
using Harvey Bradshaw Index and clinical Mayo score.
No statistically signiﬁcant difference in median TLs and
ADA rates were observed after switch.26
Based on the accumulating data, the ECCO statement
on biosimilars concluded that switching from the origi-
nator IFX to an approved biosimilar product in patients
with IBD can be regarded as safe and acceptable after
discussing with the patients individually.16 It is also
outlined that robust pharmacovigilance program is
needed for each biosimilars to support traceability and
safety. Nonetheless, because of the growing number of
biosimilars or different tender arrangements with mul-
tiple available products, physicians may need to prepare
for different scenarios including not only 1-way switch-
ing from the originator to its biosimilar, but also reverse,
multiple, or cross-switching among biosimilars. This
tendency will potentially result in a continuous change in
prescription preferences of anti-TNF drugs, leading to
the question of interchangeability. Currently, the evi-
dence supporting interchangeability between the origi-
nator and biosimilar IFX and among biosimilars is
lacking. The main concern is that substitution/inter-
changeability may lead to an increase in therapeutic
failures and decreased drug sustainability. Of note,
multiple confounders may affect drug sustainability,
including the larger number of potentially available
biological therapies and the reluctance of physicians to
strive for rigorous optimization of a given molecule, thus
the interpretation of the data will be more complex. Thus
far, no clinical trials have addressed the efﬁcacy, safety,
and immunogenicity of reverse switching (switching
from a biosimilar to its originator), multiple or repeated
switches, or cross-switching among biosimilars.
Although conﬁdence in biosimilars is growing,
immunogenicity is still one of the main concerns
considering multiple switches. Biosimilar antibodies are
not structurally identical to the originator molecule,
raising the concern that substitution in patients whose
immune system has developed tolerance to the
originator may become sensitized and produce drug-
neutralizing antibodies. The current data on immunoge-
nicity do not support this phenomenon, at least for
CT-P13.6,27,28 More recently, the NOR-SWITCH study has
reported no differences in terms of ADA formation in
patients switched to CT-P13.11 A study of Ben-Horin
et al26 showed almost complete similarity in immuno-
genicity with the presence of shared immune-dominant
epitopes in CT-P13 and IFX originator sequences.
Recent studies reported that antibodies to IFX in patients
treated with either the originator biologic or the bio-
similar present similar epitope recognition and reactivity16 April 2019  6:21 pm  ce OB
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806toward biosimilars CT-P13 and also SB2 as well as that
tested TDM assays can equivalently measure either the
reference IFX drug or any of the approved biosimilars
CT-P13 or SB2.29–32 Continuous robust capture of phar-
macovigilance data with long-term follow-ups and mul-
tiple switching sequences are needed to support decision
making around interchangeability of biosimilars.
Results from the present study show no evidence of
change in clinical efﬁcacy, safety and immunogenicity
after reverse switching from a biosimilar to the origi-
nator IFX. Clinical remission rates remained unchanged
up to the 24-week follow-up period in parallel with a
good short- and medium-term drug sustainability in both
CD and UC. No statistically signiﬁcant difference was
observed in mean serum drug TLs at 16 weeks after
switch, nor was there any change in ADA rates. Eighteen
patients of this cohort have previously been exposed to
the originator IFX and experienced back-and-forth
switch. There was also no statistically signiﬁcant
change in TLs or ADA status, nor in clinical outcomes.
Adverse event rates were also low, with 4 infusion re-
actions occurring up to week 24; all of these patients
presented detectable ADAs at baseline.
To our knowledge, this is the ﬁrst cohort to evaluate
reverse switching from a biosimilar to the originator IFX.
Strengths of our study include a robust unselected,
consecutive patient cohort with harmonized follow-up
and monitoring practices across all the centers. A
further advantage of the cohort is that a substantial
number of patients have had previous exposure to the
originator IFX before being treated with the biosimilar
(multiple switches). A possible shortcoming of or study
is that it provides only short- and medium-term follow-
up (24 weeks).
Conclusions
According to our knowledge, this is the ﬁrst real-life
cohort on mandatory reverse switch from biosimilar to
originator IFX in IBD patients. No signiﬁcant changes
were observed in clinical remission rates, drug TLs, or
ADA status after the reverse switch during a 24-week
follow-up, in parallel with good short-term drug sus-
tainability. No new safety signals were detected.
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Figure 1. Trough levels in IBD




















Supplementary Figure 2. Trough levels in CD patients before










Supplementary Figure 3. Trough levels in UC patients before
and after reverse switch.





















































































































Supplementary Table 1. Trough Levels and Anti-Drug Antibodies in CD Patients











Serum IFX trough level, mg/mL 4.89  4.39 5.33  4.58
4.98  4.31 4.41 4.94 5.31  4.32 5.47  6.01
Anti-drug antibody positivity (>10 ng/mL)
17.3 15.3
High anti-drug antibody positivity (>200 ng/mL)c
8.2 8.2
Values are mean  SD or %.
CD, Crohn’s disease; IFX, inﬂiximab.
aIFX dose: 5 mg/kg of body weight.
bIFX dose: 10 mg/kg of body weight
c Q11.
Supplementary Table 2. Trough Levels and Anti-Drug Antibodies in UC Patients











Serum IFX trough level, mg/mL 6.66  5.41 6.81  5.84
6.41  5.37 8.44  6.17 6.05  5.48 12.13  6.31
Anti-drug antibody positivity (>10 ng/mL)
12.5 21.9
High anti-drug antibody positivity (>200 ng/mL)c
9.4 9.4
Values are mean  SD or %.
IFX, inﬂiximab; UC, ulcerative colitis
aIFX dose: 5 mg/kg of body weight.
bIFX dose: 10 mg/kg of body weight.
c Q12.
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